Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13002472 | 0.84 | TSHR (0.52) | CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL13002467 | 0.81 | CYP11B2 (0.41) | CYP11B1CYP11B2CYP1A2CYP2D6AVPR1A | |
| SCHEMBL14996186 | 0.75 | CYP11B2 (0.42) | CYP11B2CYP1A2CYP2D6AVPR1A | |
| SCHEMBL3760445 | 0.72 | AVPR1A (0.32) | AVPR1A | |
| SCHEMBL14996183 | 0.69 | CYP11B2 (0.38) | CYP11B1CYP11B2CYP1A2CYP2D6AVPR1A | |
| SCHEMBL13002490 | 0.68 | S1PR1 (0.35) | CYP3A4CYP1A2CYP2D6HPGDNPC1 | |
| SCHEMBL8028802 | 0.66 | BRD4 (0.50) | CYP11B1CYP11B2TSHRAVPR1AHPGD | |
| SCHEMBL12841365 | 0.66 | TSHR (0.62) | CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL12841355 | 0.66 | TSHR (0.50) | CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2 | |
| Trifluoroacetic Acid SCHEMBL3760442 | 0.66 | CYP11B1 (0.34) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | CYP17A1 1100/4885CYP3A4 8/4885CYP19A1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.